ABX464-906
12 evidence topics · 3 sources
Objective
Location and study date
Trial dates and status in the EU register
| Field | Register entry |
|---|---|
| Protocol code | “Protocol code: ABX464-906” |
| Location | “Locations France” |
| Start of trial | “Start of trial 13/06/2024” |
| End of trial | “End of trial 20/02/2025” |
Study design
Phase 1, two-part, open-label, single-sequence design
Drug-drug interaction trials described in the Form 20-F
Eligibility criteria
Participant type, age, and sex in the EU register
| Field | Register entry |
|---|---|
| Participants type | “Participants type Healthy volunteers” |
| Age range | “Age range 18-64 years” |
| Population named in the title | “healthy male participants” |
Treatment
Single and multiple doses of obefazimod with rosuvastatin
Investigational medicinal product details not yet public
Study outcomes
Rationale for using rosuvastatin pharmacokinetics as the study endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants in the EU register
Enrollment in the two drug-drug interaction trials stated in the Form 20-F
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary
ABX464-906 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (13 June 2024 to 20 February 2025), one site in France, and 24 planned healthy volunteers aged 18 to 64 years; the 20-F reports two drug-drug interaction trials with 24 and 36 enrolled healthy volunteers. The objectives, endpoints, doses, and eligibility criteria are not public, and the summary of results is deferred under the rules for category 1 trials until 20 August 2027. The register limits the population to healthy men. No pharmacokinetic or safety result has been published.